Please provide your email address to receive an email when new articles are posted on . A sutureless aortic prosthesis for use in standard-risk surgical patients was associated with positive outcomes ...
In a safety communication issued today, the US Food and Drug Administration is reminding physicians and patients of the need for lifelong imaging follow-up, on a yearly basis, for type III endoleaks ...
The FDA continues to investigate and urgently warn about the dangers posed by certain medical devices manufactured by Endologix Inc., specifically the AFX Endovascular AAA System. These devices are ...
Endologix is recalling all of its AFX endovascular abdominal aortic aneurysm (AAA) systems after continued reports of type III endoleaks. The US Food and Drug Administration (FDA) has identified this ...
IRVINE, California - Endologix, Inc., developer and marketer of minimally invasive treatments for aortic disorders, announced today that the first U.S. commercial implant of the Company's AFX™ ...
IRVINE, Calif.--(BUSINESS WIRE)--Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received notice that the U.S. Food ...